Journal Article
. 2016 Mar; 141(1):2-9.
doi: 10.1016/j.ygyno.2016.02.021.

Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers

Lorna Rodriguez-Rodriguez 1 Kim M Hirshfield 2 Veronica Rojas 3 Robert S DiPaola 2 Darlene Gibbon 2 Mira Hellmann 4 Sara Isani 2 Aliza Leiser 2 Gregory M Riedlinger 2 Allison Wagreich 5 Siraj M Ali 6 Julia A Elvin 6 Vincent A Miller 6 Shridar Ganesan 7 
  • PMID: 27016222
  •     57 References
  •     7 citations


Objective: To determine the feasibility and clinical utility of using comprehensive genomic profiling (CGP) in the course of clinical care to identify clinically relevant tumor genomic alterations for patients with either rare or refractory gynecologic cancers to facilitate point-of-care management. Use of an expert, multidisciplinary, institutional molecular tumor board (MTB) assessment is discussed regarding input on putative targeted options for individualized therapy.

Methods: A prospective clinical trial is ongoing. We report on the initial 69 patients with gynecologic cancers that were either rare or refractory to standard therapy. CGP was performed by Foundation Medicine, Inc. Genomic alterations were reviewed by members of an MTB. Consensus recommendations on genomically targeted, FDA-approved, on- and off-label therapies and clinical trials were sent to the treating physician, and decisions and outcomes were assessed.

Results: Study outcomes were available for 64 patients. The mean number of genes altered per tumor was 4.97 (median=4; range, 1-26), and the average turnaround time from testing laboratory report to generation of formal recommendations was approximately three weeks. Evaluation of genomic and clinical data by the MTB led to generation of targeted treatment options in all 64 patients, and the percentage of patients for whom one or more of these recommendations were implemented by the treating physician was 39%. Sixty-four percent of the patients receiving targeted therapy based on a CGP result experienced radiologic response or showed evidence of clinical benefit or stable disease.

Conclusion: These data suggest that an institutional MTB is a feasible venue for reviewing tumor genomic profiling results and generating clinical recommendations. These data also support the need for further studies and guidelines on clinical decision making with greater availability of broad genomically based diagnostics.

Keywords: Genomic profiling; Gynecologic cancer; Molecular tumor board; Next-generation sequencing; Point-of-care; Precision medicine.

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Diego A Garcia-Dios, Diether Lambrechts, +14 authors, Frédéric Amant.
Gynecol Oncol, 2012 Dec 12; 128(2). PMID: 23219661
NCI-MATCH launch highlights new trial design in precision-medicine era.
Caroline McNeil.
J Natl Cancer Inst, 2015 Jul 05; 107(7). PMID: 26142446
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, +10 authors, Nickolas Papadopoulos.
Science, 2010 Sep 10; 330(6001). PMID: 20826764    Free PMC article.
Highly Cited.
Next-generation sequencing to guide cancer therapy.
Jeffrey Gagan, Eliezer M Van Allen.
Genome Med, 2015 Jul 30; 7(1). PMID: 26221189    Free PMC article.
Highly Cited. Review.
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Laura J Tafe, Ivan P Gorlov, +16 authors, Mary D Chamberlin.
Oncologist, 2015 Jul 25; 20(9). PMID: 26205736    Free PMC article.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Siming Zhao, Murim Choi, +31 authors, Alessandro D Santin.
Proc Natl Acad Sci U S A, 2013 Jan 30; 110(8). PMID: 23359684    Free PMC article.
Highly Cited.
Radiation and ATM inhibition: the heart of the matter.
Ester M Hammond, Ruth J Muschel.
J Clin Invest, 2014 Jul 19; 124(8). PMID: 25036714    Free PMC article.
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Zhigang C Wang, Nicolai Juul Birkbak, +19 authors, Ursula A Matulonis.
Clin Cancer Res, 2012 Aug 23; 18(20). PMID: 22912389    Free PMC article.
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Julia Willner, Kaitlyn Wurz, +4 authors, Elizabeth M Swisher.
Hum Pathol, 2007 Jan 30; 38(4). PMID: 17258789
Mutational landscape and significance across 12 major cancer types.
Cyriac Kandoth, Michael D McLellan, +16 authors, Li Ding.
Nature, 2013 Oct 18; 502(7471). PMID: 24132290    Free PMC article.
Highly Cited.
The mutational landscape of endometrial cancer.
Bo Hong, Matthieu Le Gallo, Daphne W Bell.
Curr Opin Genet Dev, 2015 Jan 27; 30. PMID: 25622247    Free PMC article.
Bokhman's dualistic model of endometrial carcinoma. Revisited.
Robert J Kurman, Kala Visvanathan, Ie-Ming Shih.
Gynecol Oncol, 2013 Apr 16; 129(2). PMID: 23582581
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
Robert J Kurman, Ie-Ming Shih.
Hum Pathol, 2011 Jun 21; 42(7). PMID: 21683865    Free PMC article.
Highly Cited. Review.
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
Ie-Ming Shih, Robert J Kurman.
Am J Pathol, 2004 Apr 28; 164(5). PMID: 15111296    Free PMC article.
Highly Cited. Review.
On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Maria Schwaederle, Gregory A Daniels, +5 authors, Razelle Kurzrock.
Mol Cancer Ther, 2015 Apr 09; 14(6). PMID: 25852059
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
David S P Tan, Marjan Iravani, +19 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2011 Mar 18; 17(6). PMID: 21411445
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
Jennifer Wheler, Apostolia M Tsimberidou, +8 authors, Razelle Kurzrock.
Clin Cancer Res, 2012 Mar 29; 18(10). PMID: 22452943    Free PMC article.
GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.
Yingdong Zhao, Eric C Polley, +10 authors, Richard M Simon.
Cancer Inform, 2015 Apr 11; 14(Suppl 2). PMID: 25861217    Free PMC article.
Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.
Christopher H Bailey, Gayle Jameson, +4 authors, Glen J Weiss.
J Cancer, 2012 Jan 03; 3. PMID: 22211140    Free PMC article.
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
Anthony W Tolcher, Khurum Khan, +22 authors, Johann S de Bono.
Clin Cancer Res, 2014 Dec 18; 21(4). PMID: 25516890    Free PMC article.
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Brian M Slomovitz, Yunyun Jiang, +10 authors, Robert L Coleman.
J Clin Oncol, 2015 Jan 28; 33(8). PMID: 25624430    Free PMC article.
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
Jennifer Wheler, Apostolia M Tsimberidou, +5 authors, Razelle Kurzrock.
Cancer, 2009 Jan 24; 115(5). PMID: 19165805
Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Lluis Catasus, Emanuela D'Angelo, +2 authors, Jaime Prat.
Mod Pathol, 2010 Feb 23; 23(5). PMID: 20173732
Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
Gad Singer, Ie-Ming Shih, +2 authors, Robert J Kurman.
Int J Gynecol Pathol, 2002 Dec 24; 22(1). PMID: 12496696
Integrated genomic analyses of ovarian carcinoma.
Cancer Genome Atlas Research Network.
Nature, 2011 Jul 02; 474(7353). PMID: 21720365    Free PMC article.
Highly Cited.
Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
Carmela De Marco, Nicola Rinaldo, +10 authors, Giuseppe Viglietto.
PLoS One, 2013 Feb 15; 8(2). PMID: 23408974    Free PMC article.
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Lydia W T Cheung, Bryan T Hennessy, +14 authors, Gordon B Mills.
Cancer Discov, 2011 Oct 11; 1(2). PMID: 21984976    Free PMC article.
Highly Cited.
Designing transformative clinical trials in the cancer genome era.
Stefan Sleijfer, Jan Bogaerts, Lillian L Siu.
J Clin Oncol, 2013 Apr 17; 31(15). PMID: 23589555
The landscape of precision cancer medicine clinical trials in the United States.
Nitin Roper, Kristian D Stensland, Ryan Hendricks, Matthew D Galsky.
Cancer Treat Rev, 2015 Apr 13; 41(5). PMID: 25864024
Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Lluis Catasús, Elena Bussaglia, +4 authors, Jaime Prat.
Hum Pathol, 2005 Jan 26; 35(11). PMID: 15668893
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.
Apostolia-Maria Tsimberidou, Sijin Wen, +10 authors, Donald Berry.
Clin Cancer Res, 2014 Jul 06; 20(18). PMID: 24987059    Free PMC article.
Highly Cited.
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Michael S Anglesio, Stefan Kommoss, +22 authors, Jessica N McAlpine.
J Pathol, 2012 Aug 18; 229(1). PMID: 22899400
Use of mutation profiles to refine the classification of endometrial carcinomas.
Melissa K McConechy, Jiarui Ding, +17 authors, David G Huntsman.
J Pathol, 2012 Jun 02; 228(1). PMID: 22653804    Free PMC article.
Highly Cited.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, +21 authors, SHIVA investigators.
Lancet Oncol, 2015 Sep 08; 16(13). PMID: 26342236
Highly Cited.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Two pathogenetic types of endometrial carcinoma.
J V Bokhman.
Gynecol Oncol, 1983 Feb 01; 15(1). PMID: 6822361
Highly Cited.
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
Garrett M Frampton, Alex Fichtenholtz, +42 authors, Roman Yelensky.
Nat Biotechnol, 2013 Oct 22; 31(11). PMID: 24142049    Free PMC article.
Highly Cited.
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
Christine M Lovly, Kimberly Brown Dahlman, +15 authors, William Pao.
PLoS One, 2012 Apr 27; 7(4). PMID: 22536370    Free PMC article.
Highly Cited.
Cancer statistics, 2015.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2015 Jan 07; 65(1). PMID: 25559415
Highly Cited.
The biology of uterine sarcomas: A review and update.
Hiroshi Kobayashi, Chiaki Uekuri, +4 authors, Hiroshi Shigetomi.
Mol Clin Oncol, 2014 Mar 22; 1(4). PMID: 24649216    Free PMC article.
BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Rebecca Byler Dann, Julie A DeLoia, +5 authors, Thomas C Krivak.
Gynecol Oncol, 2012 Mar 13; 125(3). PMID: 22406760
ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, +41 authors, David G Huntsman.
N Engl J Med, 2010 Oct 15; 363(16). PMID: 20942669    Free PMC article.
Highly Cited.
I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.
Carrie Printz.
Cancer, 2013 May 23; 119(11). PMID: 23695808
Integrated genomic characterization of endometrial carcinoma.
Cancer Genome Atlas Research Network, Cyriac Kandoth, +16 authors, Douglas A Levine.
Nature, 2013 May 03; 497(7447). PMID: 23636398    Free PMC article.
Highly Cited.
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuan-Ting Kuo, Tsui-Lien Mao, +8 authors, Ie-Ming Shih.
Am J Pathol, 2009 Apr 08; 174(5). PMID: 19349352    Free PMC article.
Highly Cited.
Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.
Sandra E Brooks, Min Zhan, Timothy Cote, Claudia R Baquet.
Gynecol Oncol, 2004 Mar 30; 93(1). PMID: 15047237
Molecular characterization of 103 ovarian serous and mucinous tumors.
Ildikó Vereczkey, Orsolya Serester, +4 authors, Erika Tóth.
Pathol Oncol Res, 2010 Dec 08; 17(3). PMID: 21136228
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
Fabrice André, Thomas Bachelot, +17 authors, Hervé Bonnefoi.
Lancet Oncol, 2014 Feb 11; 15(3). PMID: 24508104
Highly Cited.
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, +25 authors, Paul A Bunn.
JAMA, 2014 May 23; 311(19). PMID: 24846037    Free PMC article.
Highly Cited.
Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.
John Moroney, Jennifer Wheler, +7 authors, Razelle Kurzrock.
Gynecol Oncol, 2010 Mar 30; 117(3). PMID: 20347123    Free PMC article.
Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, +80 authors, David D L Bowtell.
Nature, 2015 May 29; 521(7553). PMID: 26017449
Highly Cited.
Progress in the PROSPECT trial: precision treatment for rectal cancer?
Martin R Weiser, Alessandro Fichera, +2 authors, Y Nancy You.
Bull Am Coll Surg, 2015 May 06; 100(4). PMID: 25939207
Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Maria Schwaederle, Barbara A Parker, +11 authors, Razelle Kurzrock.
Oncologist, 2014 May 07; 19(6). PMID: 24797821    Free PMC article.
Highly Cited.
Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy.
Christian L Barrett, Christopher DeBoever, +3 authors, Kelly A Frazer.
Proc Natl Acad Sci U S A, 2015 May 28; 112(23). PMID: 26015570    Free PMC article.
Origins and molecular pathology of ovarian cancer.
Debra A Bell.
Mod Pathol, 2005 Mar 12; 18 Suppl 2. PMID: 15761464
Highly Cited. Review.
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
Gad Singer, Robert Oldt, +4 authors, Ie-Ming Shih.
J Natl Cancer Inst, 2003 Mar 20; 95(6). PMID: 12644542
Highly Cited.
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
R J Kurman.
Ann Oncol, 2013 Dec 07; 24 Suppl 10. PMID: 24265397
Highly Cited. Review.
Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.
Anna V Gaponova, Alexander Y Deneka, +7 authors, Ilya G Serebriiskii.
Oncotarget, 2016 Nov 20; 8(12). PMID: 27863405    Free PMC article.
Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine Applications in Oncology.
David J Foran, Wenjin Chen, +8 authors, Robert S DiPaola.
Cancer Inform, 2017 May 05; 16. PMID: 28469389    Free PMC article.
Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.
Munveer S Bhangoo, Peter Boasberg, +4 authors, Samuel J Klempner.
Oncologist, 2018 Feb 02; 23(5). PMID: 29386312    Free PMC article.
Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
Hossein Taghizadeh, Robert M Mader, +7 authors, Gerald W Prager.
Oncologist, 2020 May 06; 25(7). PMID: 32369643    Free PMC article.
Factors that Lengthen Patient Hospitalizations Following Laparoscopic Hysterectomy.
Laura Ramirez-Caban, Akshaya Kannan, +3 authors, E Britton Chahine.
JSLS, 2020 Jul 28; 24(3). PMID: 32714003    Free PMC article.
Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens.
Margaret A Hay, Eric A Severson, +4 authors, James L Chen.
JCO Precis Oncol, 2020 Sep 15; 4. PMID: 32923870    Free PMC article.
Survival outcomes are associated with genomic instability in luminal breast cancers.
Lydia King, Andrew Flaus, Emma Holian, Aaron Golden.
PLoS One, 2021 Feb 04; 16(2). PMID: 33534788    Free PMC article.